Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classifica tra le azioni #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Prezzo delle azioni
$4.74
Ultima sincronizzazione: 2026-08-31
Capitalizzazione di mercato
$372.19M
Variazione (1 giorno)
-2.47%
Variazione (1 anno)
-1.04%
Paese
US
Scambia Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categoria

Cronologia dei frazionamenti azionari per Lexeo Therapeutics, Inc. Common Stock (LXEO)
L’azione Lexeo Therapeutics, Inc. Common Stock (simbolo: LXEO) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Sep 01, 2026.
Una quota di LXEO acquistata prima di Sep 01, 2026 equivale oggi a 0 quote di LXEO.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH